Clovis Oncology in brief
Clovis Oncology is an unlisted company in the Biotechnology industry, based in Boulder, Colorado, USA. It was founded in 2009. In the year to December 2021 it had sales of $149 M and a net loss of $265 M.
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Clovis Oncology
Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for Chapter 11 bankruptcy.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Clovis Oncology timeline
- 2009
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2011
- 🔔· approximateInitial public offering on Nasdaq as CLVS
- 2020
- 💰Record revenue of $165 millionFY2020, the highest of the 4 years on record.
Events of Clovis Oncology from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Clovis Oncology
- Acquisitions and changes
- Delisted: it ended its SEC registration (Form 15) on 11 July 2023.
Market cap history
World rank over time
Rank in USA: #2,408 (Jan 2020) · #2,752 (Jan 2021) · #3,463 (Jan 2022)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -177.8%
- Operating margin
- -151.8%
- Return on equity
- —
- Liabilities / assets
- 159.0%
- Net debt
- $366M
- Revenue growth
- -9.6%
- R&D / revenue
- 125.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2021 | $149M | -9.6% | $-226M | $-265M | -177.8% |
| Dec 2020 | $165M | +15.0% | $-302M | $-369M | -224.4% |
| Dec 2019 | $143M | +49.9% | $-377M | $-400M | -280.0% |
| Dec 2018 | $95M | +71.8% | $-334M | $-368M | -385.8% |
| Dec 2017 | $56M | +69287.5% | $-238M | $-346M | -624.0% |
| Dec 2016 | $0M | — | $-373M | $-349M | -436425.0% |
| Dec 2015 | — | — | $-377M | $-353M | — |
| Dec 2014 | $14M | — | $-158M | $-160M | -1175.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2021 | $-196M | $0M | $-196M | $-2.29 | — |
| Dec 2020 | $-253M | $0M | $-253M | $-4.38 | — |
| Dec 2019 | $-324M | $3M | $-327M | $-7.43 | — |
| Dec 2018 | $-366M | $9M | $-375M | $-7.07 | — |
| Dec 2017 | $-261M | $0M | $-261M | $-7.36 | — |
| Dec 2016 | $-267M | $1M | $-267M | $-9.07 | — |
| Dec 2015 | $-253M | $3M | $-256M | $-9.79 | — |
| Dec 2014 | $-117M | $2M | $-119M | $-4.72 | — |
SEC filings
- Jul 11, 20238-KCurrent reportBankruptcy · Change in control · Directors or officers changed · Other events
- Jun 30, 20238-KCurrent reportRegulation FD disclosure
- Jun 2, 20238-KCurrent reportRegulation FD disclosure · Other events
- May 3, 20238-KCurrent reportRegulation FD disclosure
- May 1, 20238-KCurrent reportAcquisition or disposal completed
- Apr 14, 20238-KCurrent reportAcquisition or disposal completed
- Apr 6, 20238-KCurrent reportMaterial agreement
- Mar 31, 20238-KCurrent reportRegulation FD disclosure
- Mar 2, 20238-KCurrent reportRegulation FD disclosure
- Feb 16, 20238-KCurrent reportDirectors or officers changed
- Feb 13, 20238-KCurrent reportRegulation FD disclosure · Other events
- Jan 12, 20238-KCurrent reportMaterial agreement · New financial obligation
Official filings of Clovis Oncology with the US Securities and Exchange Commission.
Annual results
- Revenue
- $149 M
- Operating income
- $-226 M
- Net income
- $-265 M
For year ending December-2021 · source: SEC filing
Balance sheet
- Total assets
- $473 M
- Total liabilities
- $752 M
- Total equity
- $-279 M
As of December-2021
Insider trading at Clovis Oncology#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gillian C. IVers-ReadSee Remarks | Sell | -1,675 | $0.980 | $2 K | 290,993 | Form 4 |
| filed | Thomas C. HardingSee Remarks | Sell | -788 | $0.980 | $772 | 18,590 | Form 4 |
| filed | Lindsey RolfeSee Remarks | Sell | -1,908 | $0.980 | $2 K | 111,419 | Form 4 |
| filed | Daniel W. MuehlSee Remarks | Sell | -2,513 | $0.980 | $2 K | 102,271 | Form 4 |
| filed | Paul Edward GrossSee Remarks | Sell | -2,595 | $0.980 | $3 K | 95,840 | Form 4 |
| filed | Daniel W. MuehlSee Remarks | Sell | -2,066 | $0.980 | $2 K | 104,830 | Form 4 |
| filed | Gillian C. IVers-ReadSee Remarks | Sell | -2,006 | $0.980 | $2 K | 293,612 | Form 4 |
| filed | Paul Edward GrossSee Remarks | Sell | -2,135 | $0.980 | $2 K | 98,330 | Form 4 |
Markets and events: Clovis Oncology#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Clovis Oncology scorecard#
Passes 6 of the 14 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 4). Fiscal year 2021.
Valuationnot known
Growth4 of 6
Profitability1 of 4
Financial health1 of 3
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Clovis Oncology: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 149 | 165 | 143 | 95 | 56 | 0.1 | 0 | 14 | — | — | |
| Cost of revenue | — | — | — | — | — | 0.1 | 0 | 0 | — | — | |
| Research and development | 187 | 258 | 283 | 231 | 142 | 251 | 269 | 138 | 67 | 59 | |
| Selling, general and administrative | 128 | 164 | 183 | 176 | 139 | 41 | 31 | 21 | — | — | |
| General and administrative | — | — | — | — | — | — | 31 | 21 | 17 | 11 | |
| Operating expenses | — | 467 | 520 | 429 | 293 | 373 | 377 | 172 | 84 | 74 | |
| Total costs and expenses | 375 | 467 | 520 | — | — | — | — | — | — | — | |
| Operating income | −226 | −302 | −377 | −334 | −238 | −373 | −377 | −158 | −84 | −74 | |
| Interest expense and finance costs | 34 | 31 | 19 | 13 | 10 | 8.5 | 8.4 | 2.6 | — | — | |
| Other non-operating income (expense) | −39 | −68 | −22 | −34 | −112 | −8.4 | −5.2 | 0.7 | −0.7 | −0.2 | |
| Income before tax | −265 | −370 | −399 | −367 | −350 | −381 | −382 | −158 | −84 | −74 | |
| Income tax | −0.4 | −0.5 | 1.8 | 0.6 | −3.6 | −32 | −29 | 2.3 | 0.1 | −0.0 | |
| Net income including minority interests | −265 | −369 | −400 | −368 | −346 | −349 | −353 | — | — | — | |
| Net income attributable to shareholders | −265 | −369 | −400 | −368 | −346 | −349 | −353 | −160 | −85 | −74 | |
| Earnings per share, basic | -2.29 | -4.38 | -7.43 | -7.07 | -7.36 | -9.07 | -9.79 | -4.72 | -2.95 | -2.97 | |
| Earnings per share, diluted | -2.29 | -4.38 | -7.43 | -7.07 | -7.36 | -9.07 | -9.79 | -4.72 | -2.95 | -2.97 | |
| Shares, weighted average (basic) | 116 | 84 | 54 | — | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 116 | 84 | 54 | 52 | 47 | 38 | 36 | 34 | 29 | 25 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 143 | 240 | 162 | 222 | 464 | 216 | 279 | 483 | 323 | 144 | |
| Short-term investments | — | — | 135 | 298 | 100 | — | — | — | — | — | |
| Receivables | 27 | 27 | 21 | 13 | 6.2 | 0.1 | 0 | — | — | — | |
| Inventory | 14 | 31 | 27 | 27 | 28 | 0 | — | — | — | — | |
| Other current assets | 12 | 9.1 | 19 | 8.6 | 7.5 | 6.7 | 7.7 | 4.7 | 4.4 | 0.7 | |
| Current assets | 198 | 311 | 366 | 572 | 627 | 279 | 540 | 491 | 329 | 145 | |
| Property, plant and equipment | 6.6 | 12 | 15 | 27 | 4.0 | 4.4 | 4.9 | 2.7 | 1.0 | 1.1 | |
| Goodwill | 63 | 63 | 63 | 63 | 65 | 57 | 59 | 66 | 75 | — | |
| Other intangible assets | 60 | 66 | 63 | 52 | 20 | 21 | 102 | 213 | 245 | — | |
| Total assets | 473 | 606 | 670 | 864 | 735 | 365 | 713 | 777r | 650 | 146 | |
| Accounts payable | 27 | 27 | 32 | 29 | 15 | 11 | 11 | 2.9 | 4.4 | 2.3 | |
| Current liabilities | 125 | 185 | 133 | 126 | 82 | 66r | 76 | 48 | 21 | 12 | |
| Non-current liabilities | — | — | — | — | — | — | — | — | — | 0.3 | |
| Total liabilities | 752 | 764 | 844 | 717 | 368 | 368 | 413 | 446r | 152 | 12 | |
| Retained earnings | −2,877 | −2,613 | −2,244 | −1,843 | −1,477 | −1,131 | −782 | −429 | −269 | — | |
| Shareholders' equity | −279 | −159 | −174r | 146 | 368r | −3.6r | 301 | 332 | 498 | 133 | |
| Total liabilities and equity | 473 | 606 | 670 | 864 | 735 | 365 | 713 | 777r | 650 | 146 | |
| Shares outstanding | 129 | 104 | 55 | 53 | 51 | 39 | 38 | 34 | 34 | 26 | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 8.5 | 8.2 | 7.8 | 4.6 | 2.5 | 1.1 | 0.8 | 0.4r | 0.3 | 0.4 | |
| Share-based compensation | 25 | 51 | 54 | 49 | 45 | 40 | 40 | 22 | 9.5 | 4.9 | |
| Cash from operating activities | −196 | −253 | −324 | −366 | −261 | −267 | −253 | −117 | −72 | −65 | |
| Capital expenditure | −0.3 | −0.4 | −3.3 | −9.2 | −0.5 | −0.8 | −3.0 | −2.3 | −0.1 | −1.1 | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | −9.9 | — | |
| Cash from investing activities | −0.3 | 126 | 143 | −264 | −54 | 199 | −255 | −2.3 | −10 | 0.9 | |
| Shares issued | 117 | 247 | — | 94 | 546 | 0 | 299 | 0 | 259 | 70 | |
| Cash from financing activities | 100 | 204 | 120 | 388 | 562 | 5.2 | 304 | 279 | 261 | 70 | |
| Exchange-rate effect on cash | — | — | — | — | 0.9 | −0.4 | −0.8 | −0.7 | 0.0 | 0.0 | |
| Change in cash | −97 | 78 | −60 | −242 | 248 | −63 | −204 | 159 | 179 | 5.9 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2022
Events at Clovis Oncology#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Bankruptcy or receivership 2 · Delisting notice 1 · Debt called early 2 · Change in control 1 · Acquisition or sale completed 2 · Directors and officers 4 · Material agreement 5 · New debt 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Bankruptcy or receivershipChange in controlDirectors and officersShareholder rights changed | 8-K | |
| Shareholder rights changed | 8-K | |
| Acquisition or sale completed | 8-K | |
| Acquisition or sale completed | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debt | 8-K | |
| New debt | 8-K | |
| Bankruptcy or receivershipDebt called earlyMaterial agreementNew debt | 8-K | |
| Delisting notice | 8-K | |
| Debt called early | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K/A | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K/A | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K |
As of Jul 11, 2023
Acquisitions and funding#
1 acquisitions, $185 M paid where reported · 1 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Ethical Oncology Science, S.p.A | 2013 | — | $185 M | — | Annual report |
Private share sales · funding history
H-1B hiring at Clovis Oncology#
1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $234 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Director, Pharmacovigilance Global Clinical Trials OperationNatural Sciences Managers | 1 | $234 K |
Where: Oakland, CA 1
How Clovis Oncology compares in Biotechnology
- Revenue$149 M · higher than 73% of 649
- Net margin-177.8% · higher than 31% of 407
- Revenue growth-9.6% · higher than 35% of 441
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Clovis Oncology🇺🇸 | $302 M | — | -177.8% | -9.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
How current the figures are
- Market cap:
- Jan 7, 2022 (last known)
- Annual results:
- For year ending December-2021
- Balance sheet:
- As of December-2021
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Clovis Oncology? Verify and update this profile — free
Show Clovis Oncology's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.